{"id":"placebomntx","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PlaceboMNTX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:48:28.923092+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:48:34.246620+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PlaceboMNTX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:48:34.576855+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo product, PlaceboMNTX contains no active pharmaceutical ingredient and produces therapeutic effects solely through placebo mechanisms such as patient expectation and conditioning. It is used in clinical research and potentially in clinical practice contexts where placebo response is therapeutically relevant.","oneSentence":"PlaceboMNTX is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:35.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:48:36.784785+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03283020","phase":"PHASE4","title":"Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume","status":"UNKNOWN","sponsor":"Region Örebro County","startDate":"2017-11-11","conditions":"Pharyngeal Dysfunction, Pharyngeal Swallowing","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sodium Chloride 0.9%","Methylnaltrexone","Relistor"],"phase":"marketed","status":"active","brandName":"PlaceboMNTX","genericName":"PlaceboMNTX","companyName":"Region Örebro County","companyId":"region-rebro-county","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:48:36.784785+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}